CULLINAN THERAPEUTICS, INC. Impairment of Long-Lived Assets Held-for-use
CULLINAN THERAPEUTICS, INC. (CGEM) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2022-03-17
- CULLINAN THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2021 was $0.00.
- CULLINAN THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2020 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-17 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |